ClinicalTrials.gg
CompletedNCT00240474Updated Nov 1, 2013

A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)

A Phase 4 interventional study of Telmisartan 80 mg + hydrochlorothiazide 12.5 mg and Amlodipine 10 mg + hydrochlorothiazide 12.5 mg in Hypertension, sponsored by Boehringer Ingelheim. Completed at 73 sites in 10 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
11th of 99
1,000 · median 184
Started
2002
with 3 others
Phase 4
32 of 99
1 open now
Registered
10th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 11th largest by enrollment, is one of 4 that started in 2002, is one of 32 in phase 4, and was the 10th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The primary objective of this study was test non-inferiority of telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg in comparison to amlodipine 10 mg + HCTZ 12.5 mg in reducing ambulatory systolic blood pressure (SBP) in the last 6 hours of the 24-hour dosing interval (determined by ambulatory blood pressure monitoring: ABPM) in elderly patients with predominantly systolic hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged at least 60 years old
  • mean SBP greater than 140 mmHg and mean DBP less than or equal to 95 mmHg
  • 24-hour mean ambulatory SBP greater than 125 mmHg
  • hypertensive patients not on current antihypertensive therapy or able to stop their current treatment for a period of up to eighteen weeks
  • willing and able to provide written

Exclusion criteria

Exclusion criteria:

  • women of who are NOT practicing acceptable means of
  • known or suspected secondary hypertension
  • mean SBP equal to or greater than 200 mmHg
  • hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients post-renal transplant or with only one functioning kidney
    • hypokalemia or hyperkalemia
    • uncorrected volume or sodium depletion
  • primary aldosteronism
  • hereditary fructose intolerance
  • biliary obstructive disorders
  • patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists
  • history of drug or alcohol dependency within the previous six months
  • chronic administration of any medication known to affect blood pressure, other than the trial medication
  • concurrent participation in another clinical trial or any therapy within thirty days prior to signing the consent form.
  • symptomatic congestive heart failure (New York Heart Academy () functional class CHF II-IV)
  • unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery less than three months prior to
  • stroke less than six months prior to informed consent
  • sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant arrhythmias as determined by the investigator
  • hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve
  • insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for the previous three months
  • night-shift workers who routinely sleep during the daytime and whose working hours include midnight to 4:00 AM
  • known allergic to any component of the formulations under investigation
  • concomitant therapy with lithium, cholestyramine or colestipol resins. non-compliance with study medication (defined as less than 80% or more than 120%) during the run-in period
  • current treatment with any antihypertensive agent
  • any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan, amlodipine or hydrochlorothiazide
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the last 6-hour mean (relative to dose time) in SBP as measured by 24-hour ABPM at the end-of-study visit

    Time frame: 14 weeks

Secondary outcomes

  1. Change from baseline in DBP in the last six hours of the 24-hour dose period

    Time frame: week 8 and 14

  2. Change from baseline in pulse pressure (PP) in the last six hours of the 24-hour dose period

    Time frame: week 8 and 14

  3. Change from baseline SBP and DBP for other time intervals ( i.e. 24-hour mean, morning mean (06:00-11:59), daytime mean (06:00-21:59), and night-time mean (22:00-05:59))

    Time frame: week 8 and 14

  4. Change from baseline in patient HRQL as measured by the Psychological General Well-Being (PGWB) index.

    Time frame: week 8 and 14

  5. Change from baseline in SBP in the last six hours of the 24-hour dose period (as measured by 24-hour ABPM).

    Time frame: 8 weeks

  6. Proportion of patients achieving a target response in SBP

    Time frame: 14 weeks

  7. Proportion of patients achieving SBP control

    Time frame: 14 weeks

  8. Proportion of patients achieving normal blood pressure

    Time frame: 14 weeks

  9. Proportion of patients achieving high-normal blood pressure

    Time frame: 14 weeks

  10. Change from baseline in trough seated SBP

    Time frame: 14 weeks

  11. Change from baseline in trough seated DBP

    Time frame: 14 weeks

  12. Safety and tolerability of the combination of telmisartan 80 mg and HCTZ 12.5 mg compared with amlodipine 10 mg and HCTZ 12.5 mg

    Time frame: 14 weeks

07

Study locations

73 sites
  • A.C.Z. Antwerpen/Stuyvenberg
    Antwerpen, 2060, Belgium
  • Boehringer Ingelheim Investigational Site
    Aywaille, 4920, Belgium
  • A.Z. VUB
    Brussels, 1090, Belgium
  • C.H.U. Liège (Ourthe-Amblève)
    Esneux, 4130, Belgium
  • Boehringer Ingelheim Investigational Site
    Christianfeld, DK-6070, Denmark
  • Boehringer Ingelheim Investigational Site
    Haderslev, DK-6100, Denmark
  • Boehringer Ingelheim Investigational Site
    Herning, DK-7400, Denmark
  • Boehringer Ingelheim Investigational Site
    Hvidovre, DK-2650, Denmark
  • Boehringer Ingelheim Investigational Site
    Odder, 8300, Denmark
  • Boehringer Ingelheim Investigational Site
    Rødovre, DK-2610, Denmark
  • Boehringer Ingelheim Investigational Site
    Vildberg, DK-7480, Denmark
  • Boehringer Ingelheim Investigational Site
    Vildbjerg, DK-7480, Denmark
  • Boehringer Ingelheim Investigational Site
    Vinderup, DK-7830, Denmark
  • Boehringer Ingelheim Investigational Site
    Åbenrå, DK-6200, Denmark
  • Diacor
    Helsinki, FIN-00530, Finland
  • Kiljava Medical Research
    Hyvinkää, FIN-05800, Finland
  • Hämeenlinnan lääkäriasema Oy, Linnan klinikka
    Hämeenlinna, FIN-13100, Finland
  • Boehringer Ingelheim Investigational Site
    Jyväskylä, FIN-40100, Finland
  • Kouvolan lääkäriasema
    Kouvola, FIN-45100, Finland
  • Hatanpään terveyskeskussairaala
    Tampere, FIN-33100, Finland
  • Boehringer Ingelheim Investigational Site
    Angers, France
  • Boehringer Ingelheim Investigational Site
    Ay, France
  • Boehringer Ingelheim Investigational Site
    Château Gontier Bazougues, 53200, France
  • Boehringer Ingelheim Investigational Site
    Jarny, 54800, France
  • Hôpital de la Timone
    Marseille cedex 05, 13385, France
  • Boehringer Ingelheim Investigational Site
    Mayenne, 53100, France
  • Boehringer Ingelheim Investigational Site
    Berlin, 12459, Germany
  • Boehringer Ingelheim Investigational Site
    Berlin, 13051, Germany
  • Boehringer Ingelheim Investigational Site
    Ellefeld, 08236, Germany
  • Boehringer Ingelheim Investigational Site
    Esslingen, 73733, Germany
  • Boehringer Ingelheim Investigational Site
    Flörsheim, 65439, Germany
  • Boehringer Ingelheim Investigational Site
    Hagen, 58091, Germany
  • Boehringer Ingelheim Investigational Site
    Hatten, 26209, Germany
  • Boehringer Ingelheim Investigational Site
    Kelkheim, 65779, Germany
  • Boehringer Ingelheim Investigational Site
    Leipzig, 04329, Germany
  • Boehringer Ingelheim Investigational Site
    Marl, 45772, Germany
  • Boehringer Ingelheim Investigational Site
    Münster, 48155, Germany
  • Boehringer Ingelheim Investigational Site
    Nürnberg, 90402, Germany
  • Boehringer Ingelheim Investigational Site
    Ornbau, 91737, Germany
  • Boehringer Ingelheim Investigational Site
    Rednitzhembach, 91126, Germany
  • Boehringer Ingelheim Investigational Site
    Riesa, 01589, Germany
  • Boehringer Ingelheim Investigational Site
    Rodgau-Dudenhofen, 63110, Germany
  • Boehringer Ingelheim Investigational Site
    Straßkirchen, 94342, Germany
  • Boehringer Ingelheim Investigational Site
    Wallerfing, 94574, Germany
  • Boehringer Ingelheim Investigational Site
    Werne, 59368, Germany
  • Boehringer Ingelheim Investigational Site
    Westerkappeln, 49492, Germany
  • Deutsche Klinik für Diagnostik GmbH
    Wiesbaden, 65191, Germany
  • Evangelisches Krankenhaus
    Witten, 58455, Germany
  • 19 Redwood View
    Dublin, 24, Ireland
  • Adelaide and Meath Hospitals (incorrporating NCH)
    Dublin, 24, Ireland
  • Boehringer Ingelheim Investigational Site
    Dublin, 7, Ireland
  • Cardioperfect Research Room
    Dublin, 8, Ireland
  • Beaumont Park Clinic
    Dublin, 9, Ireland
  • Boehringer Ingelheim Investigational Site
    Kilkenny, Ireland
  • Ospedale S. Luigi - S. Currò
    Catania, 95100, Italy
  • Università di Ferrara
    Ferrara, 44100, Italy
  • Az. Osped. Universitaria "Osp. Riuniti"
    Foggia, Italy
  • Azienda Ospedaliera "Maggiore della Carità"
    Novara, 28100, Italy
  • Ospedale Scillesi d'America
    Scilla (rc), 89058, Italy
  • Ospedale Civile
    Vittorio Veneto (TV), 31029, Italy
  • Boehringer Ingelheim Investigational Site
    Beek en Donk, 5741 AR, Netherlands
  • Boehringer Ingelheim Investigational Site
    Den Haag, 2585 LJ, Netherlands
  • Boehringer Ingelheim Investigational Site
    Ewijk, 6644 CL, Netherlands
  • Boehringer Ingelheim Investigational Site
    Musselkanaal, Netherlands
  • Boehringer Ingelheim Investigational Site
    Oude Pekela, 9665 AR, Netherlands
  • Boehringer Ingelheim Investigational Site
    Rijswijk, 2281 AK, Netherlands
  • Boehringer Ingelheim Investigational Site
    Roelofarendsveen, 2371 RB, Netherlands
  • Boehringer Ingelheim Investigational Site
    Vaals, Netherlands
  • Boehringer Ingelheim Investigational Site
    Voerendaal, Netherlands
  • Boehringer Ingelheim Investigational Site
    Pretoria, 0038, South Africa
  • Avda. Menendez Pidal, s&n
    Cordoba, 14004, Spain
  • Hospital Gral de Jerez de la Frontera
    Jerez de la Frontera / Cádiz, 11407, Spain
  • Cardiology Service
    Santander, 39008, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2002, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2005
First posted
Oct 18, 2005
Start
Dec 2002
Primary completionActual
Mar 2004
Completion
Mar 2004
Last update
Nov 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00240474
First posted
Oct 18, 2005
Start date
Dec 2002
Primary completion
Mar 2004
Completion
Mar 2004
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · BIL UK / Ireland
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion